
Allena Pharmaceuticals ALNA
Quartalsbericht 2022-Q2
hinzugefügt 15.08.2022
Allena Pharmaceuticals Betriebsaufwand 2011-2026 | ALNA
Betriebsaufwand Jährlich Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 47.6 M | 32 M | 46.9 M | 35.6 M | 21 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 47.6 M | 21 M | 36.6 M |
Betriebsaufwand Vierteljährlich Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 6.92 M | 11.6 M | 10.1 M | 12.4 M | 13.7 M | 11.4 M | 9.98 M | 7.92 M | 6.56 M | 7.52 M | 11.3 M | 13.3 M | 11.3 M | 11.6 M | 9.78 M | 9.7 M | 8.14 M | 7.97 M | 6.57 M | 4.36 M | 4.48 M | 5.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13.7 M | 4.36 M | 9.19 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 0.79 | -1.15 % | $ 4.31 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
AbCellera Biologics
ABCL
|
292 M | $ 3.49 | 0.58 % | $ 1.04 B | ||
|
Frequency Therapeutics
FREQ
|
128 M | - | - | $ 528 M | ||
|
argenx SE
ARGX
|
2.27 B | $ 700.45 | -1.19 % | $ 25 B | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.6 | 1.41 % | $ 8.66 B | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 7.81 | -2.01 % | $ 6.83 B | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 225.98 | -1.32 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
334 M | $ 4.13 | -5.06 % | $ 105 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | ||
|
BioCardia
BCDA
|
15.7 M | $ 1.26 | -0.79 % | $ 26.7 M | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 14.2 | -0.7 % | $ 208 M | ||
|
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 91.19 | 1.21 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.44 | -1.37 % | $ 367 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 6.68 | -4.57 % | $ 183 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | ||
|
Burford Capital Limited
BUR
|
106 M | $ 7.92 | 1.67 % | $ 1.31 B | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.54 | -5.22 % | $ 16 M | ||
|
Certara
CERT
|
237 M | $ 6.67 | 1.6 % | $ 1.07 B | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.6 | -4.0 % | $ 7.83 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M |